Recommendations for the treatment of Sjögren's syndrome (Q38584878)

4 September 2017

title

Recommendations for the treatment of Sjögren's syndrome (English)

1 reference

Tatiana Nayara Libório-Kimura

4 September 2017

author

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Virgínia F. Trevisani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Silvia V Lourenco

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

Wanderley Marques Bernardo

2 June 2020

18

object named as

Wanderley Marques Bernardo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Valéria Valim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sandra Gofinet Pasoto

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Erica Vieira Serrano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sandra Lúcia Euzébio Ribeiro

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Tania Sales de Alencar Fidelix

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Verônica Silva Vilela

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Leandro Lara do Prado

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Leandro Augusto Tanure

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Odvaldo Honor de Brito Filho

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Liliana Aparecida Pimenta de Barros

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Samira Tatiyama Miyamoto

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Maria Carmen Lopes Ferreira Silva Santos

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Luis Antonio Vieira

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Consuelo Bueno Diniz Adán

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

12 August 2015

1 reference

Revista Brasileira de reumatologia

4 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

446-457

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Genetic associations to germinal centre formation in primary Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Predictors for the development of non-Hodgkin lymphoma in primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Physical capacity in women with primary Sjögren's syndrome: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effects of exercise on aerobic capacity and fatigue in women with primary Sjogren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Influenza vaccination in autoimmune rheumatic disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Abnormal vitamin D3 metabolism in patients with primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Comparison of plasma vitamin D levels in patients with Sjögren's syndrome and healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Vitamin D in "early" primary Sjögren's syndrome: does it play a role in influencing disease phenotypes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Impact of wearing an intra-oral lubricating device on oral health in dry mouth patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren's syndrome. A double-blind crossover investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effects of gustatory stimulants of salivary secretion on salivary pH and flow in patients with Sjögren's syndrome: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Current Approach to Dry Eye Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Safety and efficacy of cyclosporine in the treatment of chronic dry eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Topical and systemic medications for the treatment of primary Sjögren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Two-year outcome of partial lacrimal punctal occlusion in the management of dry eye related to Sjögren syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Lacrimal punctum occlusion in the treatment of severe keratoconjunctivitis Sicca caused by Sjögren syndrome: a uniocular evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjögren's syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Respiratory function in systemic lupus erythematosus: relation with activity and severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Treatment of primary Sjögren's syndrome with hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Progression of salivary gland dysfunction in patients with Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Treatment of primary Sjögren syndrome with rituximab: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Intravenous Immunoglobulin and Mycophenolate Mofetil for Long-Standing Sensory Neuronopathy in Sjögren's Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Neurological Disorders in Primary Sjögren's Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Subacute aseptic meningitis as neurological manifestation of primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Interstitial lung disease in primary Sjögren syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Effect of cyclophosphamide on cytokines in patients with primary Sjögren's syndrome-associated interstitial lung disease in South China

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Pulmonary manifestations of Sjögren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Severe chronic bronchiolitis as the presenting feature of primary Sjögren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Sjögren's syndrome - not just Sicca: renal involvement in Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Hypokalemic periodic paralysis in Sjogren's syndrome secondary to distal renal tubular acidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Renal involvement in primary Sjögren's syndrome: a clinicopathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

A case of primary Sjögren's syndrome presenting primarily with central nervous system vasculitic involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: A national multicentric retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Neurological complications of primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

Livedoid vasculopathy and hypercoagulability in a patient with primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2015.07.004

10.1016/J.RBR.2015.07.004

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 June 2020

1005132014

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360421%20AND%20SRC:MED&resulttype=core&format=json